Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

Fresenius SE & Co. KGaA Call Transcript 2014

May 6, 2014

166_ip_2014-05-06_ef20e9cb-bbbd-40a2-9290-da2bb786bc29.pdf

Call Transcript

Open in viewer

Opens in your device viewer

Conference Call – Q1/14 Results

May 6, 2014

Safe Harbor Statement

This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements contained in this presentation.

Fresenius Group: Financial Results

S
l
a
e
s		 1
E
B
I
T		 1
i
N
t
e
n
c
o
m
e
/
Q
1
1
4		 €
5
2
1
2
m
,		 €
6
4
3
m		 €
2
2
8
m
h
G
t
t
t
t
r
o
w
a
c
o
n
s
a
n
t
c
u
r
r
e
n
c
y
r
a
e
s		 1
1
%		 6
%
-		 3
%
G
h
l
t
t
t
o
r
w
a
a
c
u
a
t
c
e
n
c
a
e
s
u
r
r
y
r		 7
%		 8
%
-		 2
%

1Before one-time items

Fresenius Group: Financial Results by Business Segment

Q
/
1
1
4		 F
i
r
e
s
e
n
s
u
M
d
i
l
C
e
c
a
a
r
e		 F
i
r
e
s
e
n
s
u
K
b
i
a		 F
i
r
e
s
e
n
s
u
H
l
i
e
o
s		 F
i
r
e
s
e
n
s
u
V
d
a
m
e
S
l
a
e
s
h
G
t
o
r
w		 \$
3
U
S
5
6
4
m
,
3
%		 €
2
3
1
1
m
,
%
4
-		 €
2
2
1
7
m
,
6
%
4		 €
9
1
1
m
%
4
E
B
I
T
h
G
t
o
r
w		 \$
S
U
4
4
5
m
1
0
%
-		 €
2
0
1
m
1
5
%
-		 €
1
1
4
m
3
1
%		 €
6
m
2
0
%

Q1 Business Update

Operations & Markets

Europe

  • 2% organic sales decline, mainly due to reduced HES sales and changes in Russian distribution model
  • Confirm 2% 5% 2014e organic sales growth

Asia-Pacific

  • 3% organic sales growth (10% excluding China) reflecting yoy price cut impact and discontinuation of HES200 solution in China, delayed tenders in Australia and Vietnam
  • Confirm >10% 2014e organic sales growth

HES blood volume replacement update

~€20 million sales decline Q1 yoy; €4 million sequential reduction

Q1 Business Update

Operations & Markets

h
N
A
i
t
o
r
m
e
r
c
a
l
i
l
h
h
i
f
l
d
Q
1
/
1
3
F
t
t
t
t
a
o
r
g
a
n
c
s
a
e
s
g
r
o
w
o
n
s
o
r
a
g
e-
n
a
e
-
l
h
E
2
%
5
%
2
0
1
4
i
t
t
t
+
x
p
e
c
o
o
r
g
a
n
c
s
a
e
s
g
r
o
w
-
-
(
l
)
i
-5
%
5
%
t
+
p
r
e
v
o
u
s
y
:
o
h
d
h
l
d
l
d
1
D
S
i
C
i
0.
9
%
i
i
t
t
t
g
s
o
a
g
e
o
m
o
e
e
g
a
o
s
c
e
o
n
r
u
r
u
r
r
u
r
y
r
–
-
f
f
d
d
l
i
i
E
i
D
3
1,
2
0
1
4
t
t
t
t
o
m
p
o
a
o
n
o
m
o
p
e
e
e
n
e
n
e
c.
r
r
r
u
r
x
u
l
f
l
l
f
d
F
D
A
i
t
t
P
t
R
i
t
i
t
w
a
r
n
n
g
e
e
r
o
r
u
e
r
o
c
o
p
a
n
e
-
f
h
l
k
h
l
A
i
i
i
R
ö
K
i
i
i
t
t
c
q
u
s
o
n
o
n
n
u
m
o
s
p
a
s
-
Q
d
E
P
S
t
i
i
1,
i
t
t
i
t
t
a
c
c
e
e
n
n
o
n
e
g
a
o
n
c
o
s
o
c
c
e
e
r
v
r
u
r
r
y
-
S
l
i
l
d
f
2
0
E
t
H
K
t
t
J
1
4
x
p
e
c
c
o
s
n
g
a
e
s
e
n
o
u
n
e
-
f
P
i
d
2
0
1
4
i
d
l
l
h
i
l
(
i
l.
H
S
K
)
i
h
t
t
r
o
v
e
g
u
a
n
c
e
o
r
a
o
s
p
a
s
n
c
w
-
f
Q
2
l
d
J
l
t
r
e
s
u
s
e
n
o
u
y		 Maxim
e hosp
itals
um car
Acute c
are ho
spitals
Acute c
are hos
pitals/
e clinic
post-ac
ute car
s
Post-ac
ute car
e clinic
s
Approv
al of m
unicipa
l
shareh
olders
pendin
g
ny hea
dquart
Compa
ers

1FDA may reconsider the discretion before the end of the year, if the shortage has been alleviated.

Q1 Business Update

Operations & Markets

Strong start into the year

€115 m order entry in Q1 – driven by hospital projects in emerging markets

Strategic Initiatives

Emerging markets expansion

  • Promising acquisition pipeline to expand presence in fastgrowing markets
  • Currently pursuing only small and midsize transactions

Group Financials Q1/14 − Outlook 2014

Fresenius Group: Profit and Loss Statement

/
Q
1
1
4		 /
Q
3
1
1		 G
h
Q
t
r
o
w		 /
Y
Y
1
1
4
o
l
t
a
c
a
u
t
r
a
e
s		 t
t
c
o
n
s
a
n
t
r
a
e
s
5
2
1
2
,		 4
8
9
0
,		 7
%		 1
1
%
6
3
4		 6
9
6		 8
%
-		 6
%
-
8
1
3
-		 1
6
3
-		 1
5
%		 1
3
%
3
3
1
-		 1
5
5
-		 %
1
4		 0
%
1
2
2
8		 2
2
4		 2
%		 3
%

1 2014 before Fenwal integration costs (€1 million) and the book gain from the divestment of two HELIOS hospitals (€22 million); 2013 before Fenwal integration costs (€7 million) Net income attributable to shareholders of Fresenius SE & Co. KGaA, before Fenwal integration costs (€1 million) and the book gain from the divestment of two HELIOS hospitals (€21 million); 2013 before Fenwal integration costs (€5 million)

Fresenius Kabi: EBIT Margin Fully in Line with Guidance

€
m		 Q
/
1
1
4		 Q
/
1
1
3		 G
h
t
r
o
w
E
o
p
e
u
r
M
i
a
g
n
r		 6
9
1
3.
8
%		 8
4
1
6.
2
%		 1
8
%
-
h
N
A
i
t
o
r
m
e
r
c
a
M
i
a
g
n
r		 1
4
7
3
8.
5
%		 1
5
4
3
8.
4
%		 5
%
-
f
/
/
f
i
i
i
i
i
i
A
P
L
t
A
A
s
a
a
c
c
a
n
m
e
c
a
c
a
r
r
-
M
i
a
r
g
n		 9
4
1
4
8
%		 6
5
1
9
0
%		 2
%
5
-
C
d
C
&
R
D
t
t
o
r
p
o
r
a
e
a
n
o
r
p
o
r
a
e		 6
4
-		 6
6
-		 %
3
T
l
E
B
I
T
t
o
a
M
i
a
r
g
n		 2
0
1
1
6
6
%		 2
3
7
1
8
8
%		 1
5
%
-

EBIT excluding Fenwal integration costs (€1 million)

Fresenius Helios: Sales and EBIT Growth Driven by First-Time Consolidation of Rhön Hospitals

€
m		 /
Q
1
1
4		 /
Q
1
1
3		 G
h
t
r
o
w
T
l
l
t
o
a
s
a
e
s		 1
2
2
7
,		 8
4
1		 4
6
%
E
B
I
T
f
b
l
i
h
d
l
i
i
l
i
E
t
t
s
a
s
e
c
n
c
p
o
o
o
r
M
i
g
n
a
r		 8
8
1
0.
3
%		 8
5
1
0.
3
%		 4
%
/
i
i
i
i
i
A
t
D
t
t
c
q
s
o
n
s
e
s
e
s
u
v
u
r
(
l
i
d
i
/
d
l
i
d
i
1
)
t
t
<
c
o
n
s
o
a
o
n
e
c
o
n
s
o
a
o
n
y
r		 2
6		 2
T
l
E
B
I
T
t
o
a		 1
1
4		 8
7		 3
1
%
M
i
a
r
g
n		 9
3
%		 0
3
%
1

EBIT excluding book gain from the divestment of two HELIOS hospitals (€22 million)

Cash Flow Development

€
m		 O
i
C
F
t
p
e
r
a
n
g		 C
a
p
e		 (
)
t
x
n
e		 1
F
C
h
F
l
r
e
e
a
s
o
w
/
Q
1
1
4		 L
T
M
M
i
a
r
g
n		 /
Q
1
1
4		 L
T
M
M
i
a
r
g
n		 /
Q
1
1
4		 L
T
M
M
i
a
r
g
n
2
4		 8
0
%		 6
5
-		 6
%
4
-		 2
3
-		 6
%
1
7
7		 8
0
%		 3
1
-		 4
7
%
-		 4
6		 3
3
3
%
5
4
-		 6
6
%
-		 1
-		 %
1
1
-		 5
5
-		 %
7
7
-
Co
/
te
rp
or
a
O
he
t
r		 7
-		 1
1
1
%
-		 2
-		 1
3
6
%		 9
-		 2
5
%
l.
C
F
M
ex
c		 8
5		 2
3
%
7		 9
9
-		 3
%
5
-		 4
1
-		 2
2
%
0
Gr
ou
p		 1
4
0		 9
8
%		 2
4
3
-		 5
4
%
-		 1
0
3
-		 4
4
%

1 Before acquisitions and dividends

2 Margin incl. FMC dividend

3 Understated: 4.1% excluding €31 million of capex commitments from acquisitions

Conference Call – Q1/14 Results, Fresenius SE & Co. KGaA, Investor Relations © Copyright, May 6, 2014

Fresenius Group: Financial Outlook by Business Segment Fully Confirmed / Narrowed

O
l
d		 N
e
w
F
i
r
e
s
e
n
u
s
b
i
K
a		 S
l
h
t
i
a
e
s
g
r
o
w
o
r
g
a
n
c
E
B
I
T
i
m
a
r
g
n		 3
%
%
7
–
8
1
6
%
1
%
–		 %
6
%
4
–
8
1
6
5
%
1
%
–
F
i
r
e
s
e
n
u
s
1
H
l
i
e
o
s		 l
h
S
t
i
a
e
s
g
o
r
w
o
r
g
a
n
c
E
B
I
T		 3
%
5
%
–
€
3
9
0
€
0
4
1
m
–
F
i
r
e
s
e
n
u
s
V
d
a
m
e		 l
h
S
t
i
a
e
s
g
o
r
w
o
r
g
a
n
c
h
E
B
I
T
t
g
r
o
w		 5
%
1
0
%
–
%
0
%
5
1
–

1 Excl. acquired Rhön hospitals; before integration costs for acquired hospitals net of book gain from the divestment of two HELIOS hospitals

Fresenius Group: Financial Outlook Fully Confirmed

1
G
i
d
2
0
1
4
u
a
n
c
e
h
R
t
e
v
e
n
u
e
g
r
o
w
t
t
t
a
c
o
n
s
a
n
c
u
r
r
e
n
c
y		 1
2
%
1
5
%
‒
2
h
N
i
t
t
e
n
c
o
m
e
g
r
o
w
t
t
t
a
c
o
n
s
a
n
c
e
n
c
u
r
r
y		 2
%
5
%
‒

1Guidance includes acquired Rhön hospitals

2 Net income attributable to shareholders of Fresenius SE& Co.KGaA before integration costs for Fenwal (€30-40 million after tax) and for the hospitals acquired from Rhön-Klinikum AG, net of book gain from the divestment of two HELIOS hospitals (€21 million after tax)

Attachments

Fresenius Group:

Overview – Calculation of Noncontrolling Interest

€
m		 /
Q
1
1
4		 /
F
Y
1
3
f
b
d
l
l
E
i
i
i
t
t
t
t
a
n
n
g
s
e
o
e
a
a
n
n
o
n
c
o
n
o
n
g
n
e
e
s
r
r
x
r
r		 2
6
5		 2
0
4
7
,
T
a
x
e
s		 1
3
4
-		 6
6
9
-
l
l
h
f
N
i
i
t
t
t,
t
o
n
c
o
n
r
o
n
g
n
e
r
e
s
e
r
e
o		 1
4
4
-		 2
7
7
-
d
l
F
i
M
i
C
i
t
t
r
e
s
e
n
u
s
e
c
a
a
r
e
n
e
n
c
o
m
e
n
o
b
b
l
(
/
)
i
F
i
Q
1
1
4
6
9
%
t
t
t
t
a
a
e
o
e
s
e
n
s
r
u
r
u
:
~		 0
3
1
-		 5
7
7
-
l
l
i
i
h
l
d
i
i
d
i
l
C
N
t
t
t
F
M
o
n
c
o
n
r
o
n
g
n
e
r
e
s
o
e
r
s
n
r
e
s
e
n
u
s
e
c
a
a
r
e
\$
(
/
d
d
l
Q
1
1
4
U
S
4
2
i
F
i
M
i
t
:
m
a
c
c
o
r
n
g
o
r
e
s
e
n
u
s
e
c
a
's
l
)
C
F
i
i
S
t
t
t
a
e
n
a
n
c
a
a
e
m
e
n
s
r		 3
1
-		 0
9
1
-
l
l
i
i
h
l
d
i
i
b
i
N
t
t
t
F
K
o
n
c
o
n
r
o
n
g
n
e
r
e
s
o
e
r
s
n
r
e
s
e
n
u
s
a
(
),
l
(
)
d
d
€
5
F
i
H
i
€
3
t
m
r
e
s
e
n
u
s
e
o
s
m
a
n
u
e
o
-
-
d
's
l
h
(
)
F
i
V
2
3
%
i
€
2
t
e
s
e
n
s
a
m
e
e
e
n
a
o
n
e
s
p
m
r
u
x
r
w
r
-		 0
1
-		 4
1
-
b
b
l
N
i
i
F
i
S
E
&
C
K
G
A
t
t
t
t
t
e
n
c
o
m
e
a
a
e
o
e
s
e
n
s
o
a
r
u
r
u		 2
4
8		 1
0
1
1
,

Fresenius Group: Cash Flow

€
m		 Q
/
1
1
4		 M M
L
T
i
a
r
g
n		 Q
/
1
1
3		 M M
L
T
i
a
r
g
n		 G
h Y
t
r
o
w
Y
o
C
O
i
h
F
l
t
p
e
r
a
n
g
a
s
o
w		 1
4
0		 9
8
%		 4
4
4		 1
1
9
%		 6
8
%
-
C
(
)
t
a
p
e
x
n
e		 2
4
3
-		 5
4
%
-		 1
8
8
-		 5
0
%
-		 2
9
%
-
F
C
h
F
l
r
e
e
a
s
o
w
(
b
f
d
d
d
d
)
i
i
t
i
i
i
e
o
r
e
a
c
q
u
s
o
n
s
a
n
v
e
n
s		 0
3
1
-		 %
4
4		 2
5
6		 9
%
6		 0
%
1
4
-
(
)
A
i
i
t
i
t
c
q
s
o
n
s
n
e
u		 8
7
5
-		 2
3		 --
i
i
d
d
D
e
n
s
v		 2
8
-		 5
0
-		 4
4
%
F
C
h
F
l
r
e
e
a
s
o
w
(
f
d
d
d
d
)
t
i
i
t
i
i
i
a
e
r
a
c
q
u
s
o
n
s
a
n
v
e
n
s		 0
0
1
6
-
,		 %
1
4
6
-		 2
2
9		 0
3
%		 --

Cash Flow Development LTM

€
m		 O
i
C
F
t
p
e
r
a
n
g		 C
a
p
e
x		 (
)
t
n
e		 1
C
h
l
F
F
r
e
e
a
s
o
w
/
L
T
M
Q
1
1
4		 L
T
M
M
in
a
rg		 /
L
T
M
Q
1
1
4		 L
T
M
M
in
a
rg		 /
L
T
M
Q
1
1
4		 L
T
M
M
in
a
rg
3
9
8		 8
0
%		 3
2
0
-		 6
%
4
-		 8
7		 6
%
1
3
0
2		 8
0
%		 1
7
9
-		 4
7
%
-		 1
2
3		 3
3
3
%
6
8
-		 6
6
%
-		 1
1
-		 %
1
1
-		 9
7
-		 %
7
7
-
Co
/
te
rp
or
a
O
he
t
r		 9 1
1
1
%
-		 1
1
-		 1
3
6
%		 2
-		 2
5
%
l.
F
M
C
ex
c		 2
7
1		 2
3
%
7		 2
5
1
-		 3
%
5
-		 9
1
1		 2
2
0
%
Gr
ou
p		 2
0
1
6
,		 9
8
%		 1
1
0
2
-
,		 5
4
%
-		 9
1
4		 4
4
%

1 Before Acquisitions and Dividends

2 Incl. FMC dividend

3 Understated: 4.1% excluding €31 million of capex commitments from acquisitions

Margin = in % of sales

Conference Call – Q1/14 Results, Fresenius SE & Co. KGaA, Investor Relations © Copyright, May 6, 2014

Fresenius Group: Debt and Interest Ratios

12014 before integration costs for Fenwal (€1 million) and the book gain from the divestment of two HELIOS hospitals (€22 million)

2Pro forma acquired hospitals from Rhön-Klinikum

32013 before integration costs for Fenwal (€54 million); debt excluding advances of €2.18 bn for the acquisition of hospitals from Rhön-Klinikum

Fresenius Kabi: Organic Sales Growth in Line with Expectations

€
m		 Q
/
1
1
4		 Q
/
1
1
3		 O
i
r
g
a
n
c
G
h
t
r
o
w
f
h
I
i
T
n
o
n
e
p
u
s
r
a
y		 2
3
0		 2
0
5		 %
1
-
I.
V
D
r
u
g
s		 4
4
1		 6
0
4		 0
%
C
l
i
i
l
i
i
N
t
t
n
c
a
o
n
u
r		 3
8
1		 3
2
6		 2
%
d
l
/
M
i
D
i
e
c
a
e
c
e
s
v
f
h
l
i
T
T
a
n
s
s
o
n
e
c
n
o
o
g
r
u
y		 2
2
4		 2
2
4		 3
%
T
l
l
t
o
a
s
a
e
s		 1
2
1
3
,		 1
2
6
0
,		 1
%

Fresenius Kabi: Organic Sales Growth in Line with Expectations

€
m		 /
Q
1
1
4		 /
Q
1
1
3		 O
i
r
g
a
n
c
G
h
t
r
o
w
E
o
p
e
u
r		 5
0
0		 5
1
7		 2
%
-
h
N
A
i
t
o
r
m
e
r
c
a		 3
8
2		 4
0
1		 0
%
f
A
i
P
i
i
s
a
a
c
c
-		 2
2
2		 2
2
3		 3
%
/
f
i
i
i
L
t
A
A
a
n
m
e
c
a
c
a
r
r		 0
9
1		 9
1
1		 %
1
1
T
l
l
t
o
a
s
a
e
s		 1
2
1
3
,		 1
2
6
0
,		 1
%

Fresenius Helios: Organic Sales Growth in Line with Expectations

€
m		 Q
/
1
1
4		 Q
/
1
1
3		 G
h
t
r
o
w
b
l
h
d
l
f
l
E
i
i
i
i
t
t
s
a
s
e
c
n
c
p
o
o
o
r		 8
5
7		 8
2
6		 4
%
A
i
i
i
t
c
q
s
o
n
s
(
l
i
d
i
1
)
u
t
<
c
o
n
s
o
a
o
n
y
r		 3
7
0
D
i
i
t
t
(
d
l
d
)
v
e
s
u
r
e
s
i
i
1
t
<
e
c
o
n
s
o
a
o
n
y
r		 1
5
T
l
l
t
o
a
s
a
e
s		 1
2
2
7
,		 8
4
1		 4
6
%

Fresenius Helios: Performance Indicators

/
Q
1
1
4		 /
Q
3
1
1		 C
h
a
n
g
e
1
f
h
l
N
i
t
o
o
o
s
p
a
s
A
l
i
i
t
c
u
e
c
a
r
e
c
n
c
s
-
l
P
t-
t
i
i
o
s
a
c
u
e
c
a
r
e
c
n
c
s
-		 1
0
9
8
5
2
4		 7
4
5
1
2
3		 4
7
%
6
7
%
%
4
1
f
b
d
N
o
o
e
s
A
l
i
i
t
c
u
e
c
a
r
e
c
n
c
s
-
l
i
i
P
t-
t
o
s
a
c
u
e
c
a
r
e
c
n
c
s
-		 3
3
0
0
9
,
2
7,
9
0
0
1
0
9
5,		 2
3
0
2
5
,
1
8,
8
8
5
6
1
4,
7		 0
%
4
4
8
%
1
1
%
d
A
i
i
m
o
n
s
s
s
(
)
A
i
i
t
t
t
e
e
n
p
e
n
c
u
c
a
r
a
-		 2
7
6,
6
0
0		 1
9
6,
1
0
7		 4
1
%
O
c
c
p
a
n
c
u
y
P
t-
t
o
s
a
c
e
c
a
e
u
r
-		 7
9
%		 7
9
%
l
h
f
(
d
)
A
t
t
e
a
g
e
e
n
g
o
s
a
a
s
v
r
y
y
A
t
c
e
c
a
e
u
r
-
P
t-
t
o
s
a
e
a
e
c
u
c
r
-		 6.
6
2
7.
1		 6.
6
2
7.
6

1December 31, 2013

Fresenius Helios: Sales Influence Hospital Acquisitions / Divestitures

i
i
i
A
t
c
q
s
o
n
s
u		 l
i
d
l
A
n
n
a
e
s
a
e
s
u
z
l
f
H
i
t
o
s
p
a
s
o
m
r
h
l
k
R
ö
K
i
i
n
n
u
m
-		 b
€
1
9
n
~		 l
d
d
f
7
0
%
i
t
c
o
n
s
o
a
e
a
s
o
~
J
1
2
0
1
4
a
n
u
a
r
y
,
f
2
0
%
l
d
d
i
t
c
o
n
s
o
a
e
a
s
o
~
h
2
0
M
1
1
4
a
c
r
,
l
l
l
d
H
S
K
i
i
i
t
c
o
s
n
g
s
p
e
n
n
g
D
i
i
t
t
v
e
s
u
r
e
s
l
k
H
i
B
Z
t
o
s
p
a
s
o
r
n
a
w
e
n
a
u
,		 €
9
0
m
~		 l
d
d
f
D
i
t
e
c
o
n
s
o
a
e
a
s
o
b
F
1
2
0
1
4
e
r
u
a
r
y
,

Fresenius Vamed: Excellent Sales and EBIT Growth

€
m		 /
Q
1
1
4		 /
Q
3
1
1		 G
h
t
r
o
w
b
P
j
i
t
r
o
e
c
u
s
n
e
s
s		 8
0		 8
2		 2
%
-
b
S
i
i
e
c
e
s
n
e
s
s
r
v
u		 1
1
1		 1
0
2		 9
%
T
l
l
t
o
a
s
a
e
s		 9
1
1		 8
1
4		 %
4
T
l
E
B
I
T
t
o
a		 6 5 2
0
%
M
i
a
r
g
n		 3
%
1		 2
%
7
1
O
d
i
k
t
r
e
r
n
a
e		 1
1
5		 9
3		 %
2
4
1
O
d
b
k
l
r
e
r
a
c
o
g		 1
1
7
0
,		 2
1
1
3
9
,		 %
3

Project business only

2December 31, 2013

Fresenius Group: Key Figures According to IFRS

€
m		 Q
/
1
1
4
G
U
S
A
A
P		 Q
/
4 I
1
1
F
R
S
l
S
a
e
s		 5
2
1
2
,		 5
2
5
8
,
1
E
B
I
T		 6
4
3		 6
3
0
N
i
t
t
t
e
n
e
r
e
s		 1
3
8
-		 1
3
8
-
2
N
i
t
e
n
c
o
m
e		 2
4
8		 2
4
3
3
N
i
t
e
n
c
o
m
e		 8
2
2		 2
2
3
O
C
h
f
l
i
t
p
e
r
a
n
g
a
s
o
w		 0
1
4		 1
4
2
l
h
l
B
t
t
t
n
e
e
e
o
a
a
c
s
a		 3
2
8
4
4
,		 3
4
3
2
9
,

2014 before Fenwal integration costs and the book gain from the divestment of two HELIOS hospitals.

Net income attributable to shareholders of Fresenius SE & Co. KGaA

Net income attributable to shareholders of Fresenius SE & Co. KGaA, 2014 before Fenwal integration costs and the book gain from the divestment of two HELIOS hospitals .

Share Information

Share key facts

Number of shares1 179,824,079 Ticker symbol FRE Bloomberg symbol FRE GR Reuters symbol FREG.de

WKN / ISIN 578560 / DE0005785604

ADR key facts

Ticker symbol FSNUY Depositary bank Deutsche Bank

Ratio 8 ADRs = 1 ordinary share ADR CUSIP / ISIN 35804M105 / US35804M1053 Exchange OTCQX International Premier Structure Sponsored Level I ADR

1As of March 31, 2014

Financial Calendar 2014

1
6
0
5
2
0
1
4		 l
l
k
f
/
A
G
M
i
F
M
i
t
t
n
n
a
e
n
e
a
e
e
n
g
a
n
a
n
u
r
r
u
r
,
3
1
0
7
2
0
1
4		 t
h
l
f
R
1
2
0
1
4
t
s
e
p
o
o
n
a
r
0
4
1
1
2
0
1
4		 d
t
R
1
3
2
0
1
4
t
t
s
r
e
p
o
r
o
n
q
u
a
r
e
r
–

Please note that these dates could be subject to modifications.

Contact

d
B
i
i
G
t
g
n
r
r
u		 l
S
V
P
I
R
i
F
i
S
E
&
C
K
G
A
t
t
n
e
s
o
e
a
o
n
s
e
s
e
n
s
o
a
v
r
r
u
l
h
T
e
e
p
o
n
e
:
l
i
e
-m
a
:		 9
6
2
6
0
8
2
8
4
1
7
4
5
+
-
G
d
@
f
B
i
i
i
t.
r
g
r
u
n
r
e
s
e
n
u
s
c
o
m

For further information and current news: http://www.fresenius.com

More from Fresenius SE & Co. KGaA

Major Shareholding Notification 2026
May 15
Director's Dealing 2026
May 8
Regulatory Filings 2026
May 6
Quarterly Report 2026
May 6
Major Shareholding Notification 2026
Apr 16
Annual Report 2026
Apr 16
Regulatory Filings 2026
Apr 8
Director's Dealing 2026
Apr 1
Director's Dealing 2026
Mar 20
Director's Dealing 2026
Mar 16
View all filings →